Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Thera

• 作 者: Fauzia F. Naime
• 机 构: LeforteOncologia,InstitutodoCancerDrArnaldoVieiradeCarvalho
• 出 处: 癌症治疗(英文)
• 发表日期: 2018年12期
• 关键词: PERICARDIAL EFFUSION Immunotherapy Nivolumab NON-SMALL Cell Lung Cancer (NSCLC)

Immune checkpoint inhibitors have shown to be very effective when treating lung cancer. Nivolumab, a programmed death-1 (PD-1) inhibitor has been approved for the treatment of metastatic non-squamous and squamous NSCLC. Immunotherapy with checkpoint inhib